Gyre Therapeutics (GYRE) Receives a Buy from Noble Financial
In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Gyre Therapeutics (GYRE – Research Report), with a ...
Gyre Therapeutics reports Q4 EPS 0c vs. ($1.39) last year
Reports Q4 revenue $ $27.87M consensus $23.5M…”2025 is shaping up to be a pivotal year for Gyre across both our commercial-stage and ...